Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | HPGD | P15428 | 4/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.46 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12238281 | 0.90 | MAPT (0.61) | ALDH1A1MAPTHPGDNPSR1LMNA | |
| SCHEMBL7315331 | 0.87 | ALDH1A1 (0.48) | ALDH1A1MAPTHPGDNPSR1LMNA | |
| SCHEMBL7319981 | 0.86 | ALDH1A1 (0.47) | ALDH1A1MAPTHPGDNPSR1LMNA | |
| SCHEMBL214250 | 0.85 | ALDH1A1 (0.57) | ALDH1A1MAPTHPGDNPSR1LMNA | |
| SCHEMBL7312883 | 0.85 | ALDH1A1 (0.47) | ALDH1A1MAPTHPGDNPSR1LMNA | |
| SCHEMBL7308168 | 0.85 | ALDH1A1 (0.47) | ALDH1A1MAPTHPGDNPSR1LMNA | |
| SCHEMBL8864730 | 0.84 | NPC1 (0.60) | ALDH1A1MAPTHPGDNPSR1LMNA | |
| SCHEMBL6117534 | 0.84 | MAPT (0.63) | ALDH1A1MAPTHPGDLMNACYP1A2 | |
| SCHEMBL7318422 | 0.83 | BACE1 (0.46) | ALDH1A1MAPTNPSR1SMN1; SMN2RAB9A | |
| SCHEMBL11013555 | 0.83 | BACE1 (0.46) | ALDH1A1MAPTNPSR1SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2760856-B1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2016-09-14 | — | — | EP | disclosed |
| US-8722670-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722670-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-13 | — | — | US | disclosed |
| US-20130085138-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
| WO-2013049119-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
| US-20130085138-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
| EP-0116948-B1 | (2-OXO-1,2,3,5-TETRAHYDROIMIDAZO-(2,1-B)QUINAZOLINYL)-OXYALKYL-AMIDES | SYNTEX (U.S.A.) INC. (US) | 1990-01-03 | — | — | EP | disclosed |
| US-4690925-A | ANTITHROMBOTIC ACTIVITY, CARDIOTONIC AGENTS | SYNTEX (U.S.A.) INC. (US) | 1987-09-01 | — | — | US | disclosed |
| US-4670434-A | ANTICOAGULANT, INOTROPIC AGENT | SYNTEX (U.S.A.) INC. (US) | 1987-06-02 | — | — | US | disclosed |
| US-4663320-A | ANTITUMOR AGENTS, ANTICOAGULANTS | SYNTEX (U.S.A.) INC. (US) | 1987-05-05 | — | — | US | disclosed |
| US-4551459-A | Method of treating heart failure using (2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-b]quinazolinyl)oxyalkylamides | SYNTEX (U.S.A.) INC. (US) | 1985-11-05 | — | — | US | disclosed |
| US-4490371-A | ANTICOAGULANTS, PHOSPHODIESTERASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1984-12-25 | — | — | US | disclosed |
| EP-0116948-A2 | (2-Oxo-1,2,3,5-tetrahydroimidazo-(2,1-b)quinazolinyl)-oxyalkyl-amides | SYNTEX (U.S.A.) INC. (US) | 1984-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085138-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | ALDH1A1 1942/4885MAPT 1080/4885HPGD 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.